無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国の中枢神経系(CNS)疾患治療薬のパイプライン分析

US CNS Disorders Drug Pipeline Insight 2014

発行 PNS Pharma 商品コード 311224
出版日 ページ情報 英文 1700 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
米国の中枢神経系(CNS)疾患治療薬のパイプライン分析 US CNS Disorders Drug Pipeline Insight 2014
出版日: 2014年08月01日 ページ情報: 英文 1700 Pages
概要

米国の中枢神経系(CNS)疾患市場は、医薬品産業の中でもっとも大きな区分のひとつとなっています。CNS疾患の件数が驚くべき勢いで増加している一方で、利用可能な治療法は市場の要件を満たせていません。米国市場は世界のCNS疾患治療薬市場の55%以上のシェアを占めています。

当レポートでは、米国の中枢神経系(CNS)疾患治療薬の開発動向について調査し、CNS疾患の発症数、市場への影響因子、市場課題などの分析、疾患区分・フェーズ・企業別のパイプラインの状況、上市薬の臨床プロファイルなどを詳細にわたってまとめています。

第1章 中枢神経系(CNS)疾患:イントロダクション

第2章 米国の中枢神経系(CNS)疾患市場の概要

  • 市場概要
  • 臨床パイプラインの考察

第3章 米国の中枢神経系(CNS)疾患の発症数:疾患別

  • アルツハイマー病
  • 多発性硬化症
  • てんかん
  • パーキンソン病
  • 片頭痛
  • ハンチントン病
  • 統合失調症
  • 不安症
  • 不眠症
  • 双極性障害
  • ADHD

第4章 米国の中枢神経系(CNS)疾患市場の力学

  • プラスの市場パラメーター
  • 市場の課題
  • 将来の成長機会

第5章 米国のCNS疾患治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第6章 米国のアルツハイマー病治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第7章 米国の多発性硬化症治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第8章 米国のパーキンソン病治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第9章 米国のCNS疾患/ 神経変性疾患治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第10章 米国のてんかん治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第11章 米国の片頭痛治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第12章 米国のハンチントン病治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第13章 米国の神経因性疼痛の臨床パイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第14章 米国の統合失調症の臨床試験の考察:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第15章 米国の睡眠障害治療薬のパイプライン:フェーズ・企業別

  • 臨床パイプラインの考察:フェーズ・企業別
  • 上市薬の臨床プロファイル

第16章 競合環境

  • Alkermes
  • Allergan
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical
目次

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.

The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.

"US CNS Disorders Drug Pipeline Insight 2014" Report Highlight:

  • Market Overview & Incidence by Disease
  • CNS Disorder Market Dynamics
  • CNS Disorder Pipeline by disease, Phase & Company
  • CNS Disorder Pipeline: 1083 Drugs in Pipeline
  • Majority CNS Drugs in Preclinical Phase: 396 Drugs
  • Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
  • CNS Disorder Market Drugs: 109 Drugs
  • Majority CNS Drugs Marketed for Epilepsy: 24 Drugs

Table of Contents

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview

  • 2.1 Market Overview
  • 2.2 Clinical Pipeline Insight

3. US Central Nervous System (CNS) Disorder Incidence by Disease

  • 3.1 Alzheimer's Disease
  • 3.2 Multiple Sclerosis
  • 3.3 Epilepsy
  • 3.4 Parkinson Disease
  • 3.5 Migraine
  • 3.6 Huntington's disease
  • 3.7 Schizophrenia
  • 3.8 Anxiety
  • 3.9 Insomnia
  • 3.10 Bipolar Disorder
  • 3.11 ADHD

4. US Central Nervous System (CNS) Disorder Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Market Challenges
  • 4.3 Future Growth Opportunity

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

  • 5.1 Clinical Pipeline Insight by Phase & Company
  • 5.2 Marketed Drugs Clinical Profile

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

  • 6.1 Clinical Pipeline Insight by Phase & Company
  • 6.2 Marketed Drug Clinical Profile

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

  • 7.1 Clinical Pipeline Insight by Phase & Company
  • 7.2 Marketed Drug Clinical Profile

8. US Parkinson's Disease Drug Pipeline by Phase & Company

  • 8.1 Clinical Pipeline Insight by Phase & Company
  • 8.2 Marketed Drug Clinical Profile

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

  • 9.1 Clinical Pipeline Insight by Phase & Company
  • 9.2 Marketed Drug Clinical Profile

10. US Epilepsy Drug Pipeline by Phase & Company

  • 10.1 Clinical Pipeline Insight by Phase & Company
  • 10.2 Marketed Drug Clinical Profile

11. US Migraine Drug Pipeline by Phase & Company

  • 11.1 Clinical Pipeline Insight by Phase & Company
  • 11.2 Marketed Drug Clinical Profile

12. US Huntington's Disease Drug Pipeline by Phase & Company

  • 12.1 Clinical Pipeline Insight by Phase & Company
  • 12.2 Marketed Drug Clinical Profile

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

  • 13.1 Clinical Pipeline Insight by Phase & Company
  • 13.2 Marketed Drug Clinical Profile

14. US Schizophrenia Clinical Trial Insight by Phase & Company

  • 14.1 Clinical Pipeline Insight by Phase & Company
  • 14.2 Marketed Drug Clinical Profile

15. US Sleep Disorders Drug Pipeline by Phase & Company

  • 15.1 Clinical Pipeline Insight by Phase & Company
  • 15.2 Marketed Drug Clinical Profile

16. Competitive Landscape

  • 16.1 Alkermes
  • 16.2 Allergan
  • 16.3 AstraZeneca
  • 16.4 Biogen Idec
  • 16.5 Bristol-Myers Squibb
  • 16.6 Eli Lilly
  • 16.7 GlaxoSmithKline
  • 16.8 Merck
  • 16.9 Novartis
  • 16.10 Pfizer
  • 16.11 Roche
  • 16.12 Sanofi
  • 16.13 Sunovion Pharmaceuticals
  • 16.14 Teva Pharmaceutical
  • Figure 2-1: US - CNS Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-2: US - CNS Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-3: US - CNS Disorder Drugs Clinical Pipeline by Disease (%), 2014
  • Figure 2-4: US - CNS Disorder Drugs Clinical Pipeline by Disease (Number), 2014
  • Figure 2-5: US - CNS Disorder Drugs in Research Phase by Disease (%), 2014
  • Figure 2-6: US - CNS Disorder Drugs in Research Phase by Disease (Number), 2014
  • Figure 2-7: US - CNS Disorder Drugs in Preclinical Phase by Disease (%), 2014
  • Figure 2-8: US - CNS Disorder Drugs in Preclinical Phase by Disease (Number), 2014
  • Figure 2-9: US - CNS Disorder Drugs in Clinical Phase by Disease (%), 2014
  • Figure 2-10: US - CNS Disorder Drugs in Clinical Phase by Disease (Number), 2014
  • Figure 2-11: US - CNS Disorder Drugs in Phase-0 by Disease (%), 2014
  • Figure 2-12: US - CNS Disorder Drugs in Phase-0 by Disease (Number), 2014
  • Figure 2-13: US - CNS Disorder Drugs in Phase-I by Disease (%), 2014
  • Figure 2-14: US - CNS Disorder Drugs in Phase-I by Disease (Number), 2014
  • Figure 2-15: US - CNS Disorder Drugs in Phase-I/II by Disease (%), 2014
  • Figure 2-16: US - CNS Disorder Drugs in Phase-I/II by Disease (Number), 2014
  • Figure 2-17: US - CNS Disorder Drugs in Phase-II by Disease (%), 2014
  • Figure 2-18: US - CNS Disorder Drugs in Phase-II by Disease (Number), 2014
  • Figure 2-19: US - CNS Disorder Drugs in Phase-II/III by Disease (%), 2014
  • Figure 2-20: US - CNS Disorder Drugs in Phase-II/III by Disease (Number), 2014
  • Figure 2-21: US - CNS Disorder Drugs in Phase-III by Disease (%), 2014
  • Figure 2-22: US - CNS Disorder Drugs in Phase-III by Disease (Number), 2014
  • Figure 2-23: US - CNS Disorder Drugs in Preregistration Phase by Disease (%), 2014
  • Figure 2-24: US - CNS Disorder Drugs in Preregistration Phase by Disease (Number), 2014
  • Figure 2-25: US - CNS Disorder Drugs in Registration Phase by Disease (%), 2014
  • Figure 2-26: US - CNS Disorder Drugs in Registration Phase by Disease (Number), 2014
  • Figure 2-27: US - Marketed CNS Disorder Drugs by Disease (%), 2014
  • Figure 2-28: US - Marketed CNS Disorder Drugs by Disease (Number), 2014
  • Figure 2-29: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-30: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-31: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-32: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-33: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-34: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-35: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-36: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-37: US - Epilepsy Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-38: US - Epilepsy Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-39: US - Migraine Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-40: US - Migraine Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-41: US - Huntington's Disease Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-42: US - Huntington's Disease Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-43: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-44: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-45: US - Schizophrenia Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-46: US - Schizophrenia Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 2-47: US - Sleep Disorders Drugs Clinical Pipeline by Phase (%), 2014
  • Figure 2-48: US - Sleep Disorders Drugs Clinical Pipeline by Phase (Number), 2014
  • Figure 3-1: US - Alzheimer's Disease Incidence (Million), 2013-2020
  • Figure 3-2: US - Multiple Sclerosis Incidence ('000), 2013-2020
  • Figure 3-3: US - Epilepsy Incidence (Million), 2013-2020
  • Figure 3-4: US - Parkinson's Disease Incidence (Million), 2013-2020
  • Figure 3-5: US - Migraine Incidence (Million), 2013-2020
  • Figure 3-6: US - Huntington's Disease Incidence ('000), 2013-2020
  • Figure 3-7: US - Schizophrenia Disease Incidence (Million), 2013-2020
  • Figure 3-8: US - Anxiety Disorder Incidence (Million), 2013-2020
  • Figure 3-9: US - Insomnia Incidence (Million), 2013-2020
  • Figure 3-10: US - Bipolar Disorder Incidence (Million), 2013-2020
  • Figure 3-11: US - ADHD Incidence (Million), 2013-2020
Back to Top